Contineum Therapeutics (CTNM) Income towards Parent Company (2023 - 2026)

Contineum Therapeutics' Income towards Parent Company history runs 4 years deep, the most recent figure standing at -$38.4 million for Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 76.6% year-over-year to -$38.4 million in Q1 2026; TTM through Mar 2026 was -$118.0 million, a 112.13% decrease from a year earlier, with the FY2025 full-year figure at -$115.8 million, down 174.1% from the prior year.
• Income towards Parent Company fell to -$38.4 million in Q1 2026 per CTNM's latest filing, from -$24.0 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $41.6 million in Q2 2023 and bottomed at -$38.4 million in Q1 2026.
• The 4-year median for Income towards Parent Company is -$10.3 million (2024), against an average of -$12.2 million.
• Across the five-year window, Income towards Parent Company sank 63.77% in 2024 and sank 237.7% in 2025, its largest moves.
• Year by year, Income towards Parent Company stood at -$7.3 million in 2023, then plunged by 98.57% to -$14.6 million in 2024, then sank by 64.88% to -$24.0 million in 2025, then slumped by 60.09% to -$38.4 million in 2026.
• Per Business Quant, the three latest CTNM Income towards Parent Company figures stand at -$38.4 million (Q1 2026), -$24.0 million (Q4 2025), and -$34.7 million (Q3 2025).